Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I , Spring 2005 Mon, 29 Aug 2005 Some uncritical promoters of psychiatry and its current biological treatment paradigm have declared that the introduction…
Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
The risks of the drugs far outweigh their benefits, said Vera Sharav, president of the Alliance for Human Research Protection, a New York-based consumer advocacy group.
Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.
Urge your Senators to VOTE YES for the Child Medication Safety Act (S. 4041, HR 1790) !!!
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Evidence of an association between violence and widely prescribed antidepressant drugs is the focus of this Infomail.
The New York Times reports (below) that after months of foot dragging, the FDA has finally issued additional warnings on the labels of widely
prescribed psychostimulant drugs–Ritalin, Adderall, Concerta.
The American Society of Health System Pharmacists reports that the FDA "directed all makers of ADHD stimulants in May to strengthen the wording in the "Warnings" section of the labeling "with regard to serious cardiovascular events and psychiatric events."
It is difficult to believe this latest announcement laying claim to a new "under treated" psychiatric disorder–Intermittent Explosive Disorder (IED) is not a parody !!
An investigative report in The Philadelphia Inquirer examined pharmaceutical company ties to six, tax exempt organziations that identify themselves as “patient advocacy” groups, "Each a leading advocate for patients in a disease area.”
